Abstract:Abstract The TGF-β signaling pathway governs key cellular processes under physiologic conditions and is deregulated in many pathologies, including cancer. TGF-β is a multifunctional cytokine that acts in a cell- and context-dependent manner as a tumor promoter or tumor suppressor. As a tumor promoter, the TGF-β pathway enhances cell proliferation, migratory invasion, metastatic spread within the tumor microenvironment and suppresses immunosurveillance. Collectively, the pleiotropic nature of TGF-β signaling contributes to drug resistance, tumor escape and undermines clinical response to therapy. Based upon a wealth of preclinical studies, the TGF-β pathway has been pharmacologically targeted using small molecule inhibitors, TGF-β-directed chimeric monoclonal antibodies, ligand traps, antisense oligonucleotides and vaccines that have been now evaluated in clinical trials. Here, we have assessed the safety and efficacy of TGF-β pathway antagonists from multiple drug classes that have been evaluated in completed and ongoing trials. We highlight Vactosertib, a highly potent small molecule TGF-β type 1 receptor kinase inhibitor that is well-tolerated with an acceptable safety profile that has shown efficacy against multiple types of cancer. The TGF-β ligand traps Bintrafusp alfa (a bifunctional conjugate that binds TGF-β and PD-L1), AVID200 (a computationally designed trap of TGF-β receptor ectodomains fused to an Fc domain) and Luspatercept (a recombinant fusion that links the activin receptor IIb to IgG) offer new ways to fight difficult-to-treat cancers. While TGF-β pathway antagonists are rapidly emerging as highly promising, safe and effective anticancer agents, significant challenges remain. Minimizing the unintentional inhibition of tumor-suppressing activity and inflammatory effects with the desired restraint on tumor-promoting activities has impeded the clinical development of TGF-β pathway antagonists. A better understanding of the mechanistic details of the TGF-β pathway should lead to more effective TGF-β antagonists and uncover biomarkers that better stratify patient selection, improve patient responses and further the clinical development of TGF-β antagonists.

Recent progress in TGF-β inhibitors for cancer therapy

Curcumin Inhibits Transforming Growth Factor-Beta Activity Via Inhibition of Smad Signaling in HK-2 Cells.

A Perspective on the Development of TGF-β Inhibitors for Cancer Treatment

A 3-arm study of early loading of rough-surfaced implants in the completely edentulous maxilla and in the edentulous posterior maxilla and mandible: results after 1 year of loading.

Research progress on drugs targeting the TGF-β signaling pathway in fibrotic diseases

Targeting transforming growth factor‐β signalling for cancer prevention and intervention: Recent advances in developing small molecules of natural origin

TGF-beta signal transduction: biology, function and therapy for diseases

Targeting TGF-β signal transduction for fibrosis and cancer therapy

The Role of TGF-β Signaling Pathways in Cancer and Its Potential as a Therapeutic Target

Targeting TGFβ signal transduction for cancer therapy

Targeting transforming growth factor-β signaling for enhanced cancer chemotherapy

Novel therapies emerging in oncology to target the TGF-β pathway

Exploring anti-TGF-β therapies in cancer and fibrosis.

Targeting the transforming growth factor-β signaling pathway in human cancer

TGF-β signaling in liver and gastrointestinal cancers

Targeting TGF-β Signaling in Cancer.

Transforming growth factor-β signaling: from tumor microenvironment to anticancer therapy

TGF-β-Regulated MicroRNAs and Their Function in Cancer Biology.

TGF-&beta; Signaling in Cancer Metastasis

TGF-β: A novel predictor and target for anti-PD-1/PD-L1 therapy

The TGF-β superfamily as potential therapeutic targets in pancreatic cancer